Provided by Tiger Fintech (Singapore) Pte. Ltd.

MoonLake Immunotherapeutics

10.66
+0.40003.90%
Post-market: 10.660.00000.00%19:59 EDT
Volume:4.75M
Turnover:50.42M
Market Cap:684.70M
PE:-3.82
High:10.95
Open:10.26
Low:10.11
Close:10.26
52wk High:62.75
52wk Low:5.95
Shares:64.23M
Float Shares:24.16M
Volume Ratio:0.46
T/O Rate:19.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7908
EPS(LYR):-1.8918
ROE:-40.34%
ROA:-24.99%
PB:1.94
PE(LYR):-5.63

Loading ...

Why Are MoonLake's (MLTX) Trial Setbacks Raising New Questions About Management Credibility and Regulatory Risks?

Simply Wall St.
·
Oct 11

CFO Makes Bold Move with Major Stock Purchase in MoonLake Immunotherapeutics

TIPRANKS
·
Oct 10

Moonlake Immunotherapeutics CFO Matthias Bodenstedt Reports Acquisition of Common Shares

Reuters
·
Oct 09

MoonLake Immunotherapeutics : Oppenheimer Cuts Target Price to $25 From $104

THOMSON REUTERS
·
Oct 07

MoonLake Immunotherapeutics price target lowered to $25 from $104 at Oppenheimer

TIPRANKS
·
Oct 07

LifeSci Capital Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Oct 04

Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Trevi Therapeutics (TRVI)

TIPRANKS
·
Oct 03

HC Wainwright Downgrades MoonLake Immunotherapeutics to Neutral From Buy

MT Newswires Live
·
Oct 02

MoonLake Immunotherap Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
Oct 02

MoonLake Immunotherapeutics downgraded to Neutral from Buy at H.C. Wainwright

TIPRANKS
·
Oct 02

MoonLake Immunotherapeutics : H.c. Wainwright Cuts to Neutral From Buy

THOMSON REUTERS
·
Oct 02

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Oct 02

MoonLake Immunotherapeutics Officer Chen Bihua sold 6,509,428 shares.

Filings Track
·
Oct 02

Bihua Chen, Former 10% Owner, Reports Disposal of Common Shares of Moonlake Immunotherapeutics

Reuters
·
Oct 02

Wedbush Cuts Price Target on MoonLake Immunotherapeutics to $18 From $80, Maintains Outperform Rating

MT Newswires Live
·
Sep 30

MoonLake Immunotherap Is Maintained at Outperform by Wedbush

Dow Jones
·
Sep 30

MoonLake Immunotherapeutics : Needham Cuts Target Price to $20 From $66

THOMSON REUTERS
·
Sep 30

MoonLake Immunotherapeutics downgraded to Neutral from Buy at Citi

TIPRANKS
·
Sep 30

MoonLake Immunotherapeutics : Jefferies Cuts to Hold From Buy; Cuts Target Price to $8 From $65

THOMSON REUTERS
·
Sep 30

MoonLake Immunotherapeutics : Wedbush Cuts Target Price to $18 From $80

THOMSON REUTERS
·
Sep 30